Table 3 Outcomes of study groups.
Topical gentamicin (N = 74) | Topical Saline solution (N = 72) | p-value | |
|---|---|---|---|
Surgical site occurrence, N (%) | |||
Any surgical site occurrence | 18 (24.3) | 21 (29.2) | 0.509 |
Seroma | 8 (10.8) | 13 (18.1) | 0.212 |
Hematomas | 4 (5.4) | 2 (2.8) | 0.681 |
Wound dehiscence | 2 (2.7) | 5 (6.9) | 0.272 |
Surgical site infection | 6 (8.1) | 8 (11.1) | 0.538 |
Superficial surgical site infection | 6 (8.1) | 7 (9.7) | 0.732 |
Deep surgical site infection | 0 | 1 (1.4) | 0.493 |
Mesh infection | 0 | 1 (1.4) | 0.493 |
Cultures performed | 3 (4.1) | 7 (9.7) | 0.206 |
Positive culture | 2 (2.7) | 7 (9.7) | 0.095 |
Surgical site infection treatment, N (%) | |||
Antibiotic | 3 (4.1) | 4 (5.6) | 0.717 |
Antibiotic and abscess drainage | 3 (4.2) | 3 (4.1) | 1 |
Antibiotic, abscess drainage, and remove mesh | 0 | 1 (1.4) | 0.493 |
Other complications, N (%) | 4 (5.4) | 3 (4.2) | 1 |
Clavien Dindo, N (%) | 0.564 | ||
I | 0 | 1 (1.4) | |
II | 4 (5.4) | 3 (4.2) | |
Length of stay (days), Mean ± SD | 2.32 ± 2.73 | 2.86 ± 4.15 | 0.465 |
Mortality 30 days, N (%) | 0 | 0 | |
Hernia recurrence, N (%) | 2 (2.7) | 6 (8.3) | 0.163 |
